The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. PTC Therapeutics Inc shares valued at $89,081 were sold by Boulding Mark Elliott on May 15 ’25. At $46.18 per share, Boulding Mark Elliott sold 1,929 shares. The insider’s holdings dropped to 103,901 shares worth approximately $5.3 million following the completion of this transaction.
Also, Boulding Mark Elliott sold 883 shares, netting a total of over 40,636 in proceeds. Following the sale of shares at $46.02 each, the insider now holds 103,901 shares.
Before that, Boulding Mark Elliott had added 883 shares to its account. In a trade valued at $40,640, the Officer bought PTC Therapeutics Inc shares for $46.02 each.
As published in a research note from BofA Securities on May 09, 2025, PTC Therapeutics Inc [PTCT] has been rated up from a Neutral to a Buy and the price target has been revised to $68. Analysts at Citigroup upgraded the stock from ‘”a Sell”‘ to ‘”a Neutral”‘ outlook in a report released in early May. As of March 11, 2025, BofA Securities has increased its “an Underperform” rating to a “Neutral” for PTCT. Earlier on March 07, 2025, Scotiabank initiated its rating. Their recommendation was “a Sector perform” for PTCT stock.
Analyzing PTCT Stock Performance
On last trading session,, PTC Therapeutics Inc [NASDAQ: PTCT] rose 0.31% to $50.98. The stock’s lowest price that day was $50.33, but it reached a high of $51.335 in the same session. During the last five days, there has been a drop of approximately -1.45%. Over the course of the year, PTC Therapeutics Inc shares have jumped approximately 12.94%.
Support And Resistance Levels for PTC Therapeutics Inc (PTCT)
RSI (Relative Strength Index) is 58.70 on the 14-day chart, showing neutral technical sentiment.
Is PTC Therapeutics Inc subject to short interest?
Stocks of PTC Therapeutics Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.26 million shares to 4.75 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 5.01 million shares. A decline of -5.37% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.06 of the overall float, the days-to-cover ratio (short ratio) decline to 3.06.
Which companies own the most shares of PTC Therapeutics Inc (PTCT)?
In terms of PTC Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 62 in the next 12 months, up nearly 22.0% from the previous closing price of $50.82. Analysts anticipate PTC Therapeutics Inc stock to reach 66 by 2025, with the lowest price target being 58. In spite of this, 7 analysts ranked PTC Therapeutics Inc stock as Hold at the end of 2025. On December 13, 2024, Morgan Stanley assigned a price target of “an Overweight” to the stock and upgraded coverage with a $67.
